Quantitation of HSV mass distribution in a rodent brain tumor model

[1]  H. Engelhard,et al.  Gene therapy for brain tumors , 2000, Current oncology reports.

[2]  Anna Moore,et al.  In vivo magnetic resonance imaging of transgene expression , 2000, Nature Medicine.

[3]  R. Jain,et al.  Vasculogenic mimicry: how convincing, how novel, and how significant? , 2000, The American journal of pathology.

[4]  B. Peck,et al.  Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures. , 1999, Human gene therapy.

[5]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[6]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[7]  A. Quiñones,et al.  Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. , 1999, Frontiers of radiation therapy and oncology.

[8]  Blasberg Rg,et al.  Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. , 1999 .

[9]  S. Cherry,et al.  Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals , 1999, Gene Therapy.

[10]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[11]  R. Blasberg,et al.  Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[12]  X. Breakefield,et al.  Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7 , 1999, Cancer Gene Therapy.

[13]  R Weissleder,et al.  Novel gliosarcoma cell line expressing green fluorescent protein: A model for quantitative assessment of angiogenesis. , 1998, Microvascular research.

[14]  R. Weissleder,et al.  Mapping the in vivo distribution of herpes simplex virions. , 1998, Human gene therapy.

[15]  D. Curiel,et al.  Targeted adenoviral vectors for cancer gene therapy. , 1998, Advances in experimental medicine and biology.

[16]  K. Zinn,et al.  Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5) , 1998, Gene Therapy.

[17]  A. Jacobs,et al.  Green fluorescent protein as a reporter for retrovirus and helper virus‐free HSV‐1 amplicon vector‐mediated gene transfer into neural cells in culture and in vivo , 1997, Neuroreport.

[18]  C. Fraefel,et al.  Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes , 1997, Gene Therapy.

[19]  I. Kovesdi,et al.  Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation , 1997, Cancer Immunology, Immunotherapy.

[20]  R Weissleder,et al.  MR imaging and scintigraphy of gene expression through melanin induction. , 1997, Radiology.

[21]  D. Curiel,et al.  Adenoviral/retroviral vector chimeras: a novel strategy to achieve high‐efficiency stable transduction in vivo , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  T. Cloughesy,et al.  Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. , 1997, Journal of neurosurgery.

[23]  X. Breakefield,et al.  HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. , 1997, Human gene therapy.

[24]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[25]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[26]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. J. Elliott,et al.  Controlled Modulation of BBB Permeability Using the Bradykinin Agonist, RMP-7 , 1996, Experimental Neurology.

[28]  E. Chiocca,et al.  A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. , 1996, Human gene therapy.

[29]  L. Soroceanu,et al.  The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Bartus,et al.  Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. , 1996, Immunopharmacology.

[31]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[32]  D. L. Sokol,et al.  Gene therapy: basic concepts and recent advances. , 1996, Critical reviews in eukaryotic gene expression.

[33]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[34]  R. Weissleder,et al.  Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. , 1995, Human gene therapy.

[35]  A A Szalay,et al.  Monitoring of spatial expression of firefly luciferase in transformed zebrafish. , 1995, Journal of bioluminescence and chemiluminescence.

[36]  R. Martuza,et al.  Brain Tumor Therapy Using Genetically Engineered Replication-Competent Virus , 1995 .

[37]  T. Tamiya,et al.  Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. , 1994, Human gene therapy.

[38]  C. Capen,et al.  Pathobiology of the Aging Rat , 1993 .

[39]  C. Thiemermann,et al.  The effects of endothelium‐dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside , 1988, British journal of pharmacology.

[40]  F. Hochberg,et al.  Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. , 1988, Neurosurgery.

[41]  S. Weller,et al.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant , 1988, Journal of virology.

[42]  T. Hoshino.  A commentary on the biology and growth kinetics of low-grade and high-grade gliomas. , 1984, Journal of neurosurgery.

[43]  V. Mucha,et al.  Purification and separation of enveloped and unenveloped herpes simplex virus particles. , 1975, Acta virologica.

[44]  B. Roizman,et al.  Preparation of herpes simplex virus of high titer , 1968, Journal of virology.